Literature DB >> 3504266

Young onset Parkinson's disease.

N Quinn1, P Critchley, C D Marsden.   

Abstract

We describe a personal series of 60 cases of parkinsonism with onset under the age of 40 years. Known causes for early onset of secondary parkinsonism, such as Wilson's disease or encephalitis, were excluded in every case. Two groups were identified: those with onset after the age of 21 in whom no hereditary factors could be ascertained (56 cases), and those with onset before 21 years all of whom had familial parkinsonism. In neither group have we found any association with prematurely grey hair, hypertension, diabetes, pernicious anaemia, or thyroid disorder. Among their families, we have not found any association with diabetes, pernicious anaemia, or thyroid disorder. We propose that cases of apparent idiopathic Parkinson's disease beginning between age 21-40 years should be called "young onset Parkinson's disease." Twenty percent of such patients in our series had at least one first- or second-degree relative in the same or antecedent generations with parkinsonism, but only 1.5% of their relatives at risk had parkinsonism, which is similar to the prevalence in the general population. Ten percent of these patients had at least one relative with essential tremor, but only 1.6% of their relatives at risk had tremor, which again was similar to the prevalence in the population in general. These patients with young onset Parkinson's disease responded well to levodopa therapy. However, dyskinesias and response fluctuations occurred early and frequently. The prevalence of dyskinesias and response fluctuations was strongly correlated with the duration of levodopa treatment, but not with the duration (or probably the severity) of the disease before levodopa therapy was commenced. The involuntary movements often were severe and frequently were diphasic. Despite long disease duration, the incidence of dementia in young onset patients aged less than 65 years was negligible. We believe that most, if not all, patients in this group have degenerative Lewy body idiopathic Parkinson's disease, representing the lower end of a skewed deviation for age of onset of this disease. We have so far failed to identify any additional environmental factor which may have accelerated disease onset in these patients. In contrast, cases of parkinsonism beginning before age 21 years were invariably familial. We proposed that they should be called "juvenile parkinsonism." All affected relatives with parkinsonism also had young disease onset, and all but one were siblings. None of four such patients seen by us has demented, and computed tomography (CT) scan has been normal in all four. We believe that most such patients have some form of genetically determined secondary parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3504266     DOI: 10.1002/mds.870020201

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  62 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.

Authors:  J E Nash; J M Brotchie
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

Review 3.  Cheaper, simpler, and better: tips for treating seniors with Parkinson disease.

Authors:  J Eric Ahlskog
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

Review 4.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

5.  "Silly walks" in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias.

Authors:  Evžen Růžička; Kateřina Zárubová; John G Nutt; Bastiaan R Bloem
Journal:  Mov Disord       Date:  2011-04-14       Impact factor: 10.338

6.  A controlled, longitudinal study of dementia in Parkinson's disease.

Authors:  C A Biggins; J L Boyd; F M Harrop; P Madeley; R H Mindham; J I Randall; E G Spokes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-07       Impact factor: 10.154

7.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

8.  Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study.

Authors:  Pierpaolo Turcano; Michelle M Mielke; James H Bower; Joseph E Parisi; Jeremy K Cutsforth-Gregory; J Eric Ahlskog; Rodolfo Savica
Journal:  Neurology       Date:  2018-11-07       Impact factor: 9.910

9.  Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease.

Authors:  T J Loher; J-M Burgunder; S Weber; R Sommerhalder; J K Krauss
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

10.  Locomotor response to levodopa in fluctuating Parkinson's disease.

Authors:  Steven T Moore; Hamish G MacDougall; Jean-Michel Gracies; William G Ondo
Journal:  Exp Brain Res       Date:  2007-09-08       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.